Cwm, LLC Tg Therapeutics, Inc. Transaction History

Cwm, LLC

$33.3 Billion
Q3 2025

A detailed history of Cwm, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Cwm, LLC holds 1,692 shares of TGTX stock, worth $59,423. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,692

Previous 2,164 21.81%

Holding current value

$59,423

Previous $78,000 21.79%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 15, 2025	SELL	$26.39 - $39.19 $12,456 - $18,497	-472 Reduced 21.81%	1,692 $61,000
Q2 2025 Jul 25, 2025	BUY	$33.37 - $45.51 $2,636 - $3,595	79 Added 3.79%	2,164 $78,000
Q1 2025 May 01, 2025	BUY	$27.67 - $42.99 $8,024 - $12,467	290 Added 16.16%	2,085 $82,000
Q4 2024 Feb 04, 2025	BUY	$21.31 - $35.09 $11,890 - $19,580	558 Added 45.11%	1,795 $54,000
Q3 2024 Oct 08, 2024	SELL	$17.21 - $25.28 $199,962 - $293,728	-11,619 Reduced 90.38%	1,237 $29,000
Q2 2024 Jul 09, 2024	BUY	$13.32 - $19.19 $2,304 - $3,319	173 Added 1.36%	12,856 $229,000
Q1 2024 Apr 05, 2024	BUY	$13.02 - $21.3 $6,054 - $9,904	465 Added 3.81%	12,683 $193,000
Q4 2023 Feb 01, 2024	BUY	$6.68 - $18.81 $80 - $225	12 Added 0.1%	12,218 $209,000
Q3 2023 Oct 11, 2023	SELL	$8.36 - $26.5 $200 - $636	-24 Reduced 0.2%	12,206 $102,000
Q2 2023 Aug 03, 2023	BUY	$15.48 - $35.0 $774 - $1,750	50 Added 0.41%	12,230 $304,000
Q2 2022 Jul 28, 2022	BUY	$3.74 - $10.66 $44,636 - $127,227	11,935 Added 4871.43%	12,180 $52,000
Q1 2022 Apr 21, 2022	BUY	$7.81 - $20.45 $1,913 - $5,010	245 New	245 $2,000

Others Institutions Holding TGTX

# of Institutions

405

Shares Held

91.9M

Call Options Held

2.28M

Put Options Held

1.68M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $5.1B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account